Adams C M, Eischen C M
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Cell Death Differ. 2016 Aug;23(8):1312-21. doi: 10.1038/cdd.2016.9. Epub 2016 Feb 26.
Histone deacetylase (HDAC) inhibition leads to dynamic changes in the epigenetic landscape that is postulated to alter the expression of critical mediators of cellular proliferation and death. While current HDAC inhibitors have shown to be efficacious in the treatment of specific hematologic malignancies, their therapeutic utility in epithelial-based cancers warrants further evaluation. Moreover, the mechanisms of HDAC inhibition-induced cancer cell death are not completely understood. Therefore, elucidation of the underlying pathways engaged by HDAC inhibition may enable the development of more effective therapeutic strategies. Here, we report that HDAC inhibition in human breast and lung carcinoma cells activates an apoptotic mechanism mediated by microRNA (miRNA) and induced by the oncogene MYC. Specifically, following HDAC inhibition, MYC, which normally represses miR-15 and let-7 families, transcriptionally activated their expression and MYC was required for this miRNA upregulation. As a result, transcript levels of the tumor-suppressive miR-15 and let-7 families increased, which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL, respectively. MYC was also required for the downregulation of BCL-2 and BCL-XL following HDAC inhibition. Blocking the binding sites of the miR-15 and let-7 families in the 3'-untranslated regions of BCL-2 and BCL-XL protected against HDAC inhibition-induced apoptosis. These results provide important insight into the molecular underpinnings of HDAC inhibition-induced cell death in breast and lung cancer and reveal a tumor-suppressive role for MYC-regulated miRNA that is activated with HDAC inhibition.
组蛋白去乙酰化酶(HDAC)抑制作用会导致表观遗传格局发生动态变化,据推测这种变化会改变细胞增殖和死亡关键调节因子的表达。虽然目前的HDAC抑制剂已显示出对特定血液系统恶性肿瘤的治疗效果,但其在基于上皮细胞的癌症中的治疗效用仍有待进一步评估。此外,HDAC抑制诱导癌细胞死亡的机制尚未完全明确。因此,阐明HDAC抑制作用所涉及的潜在途径可能有助于开发更有效的治疗策略。在此,我们报告HDAC抑制人乳腺癌和肺癌细胞会激活一种由微小RNA(miRNA)介导且由癌基因MYC诱导的凋亡机制。具体而言,HDAC抑制后,通常抑制miR-15和let-7家族的MYC会转录激活它们的表达,且这种miRNA上调需要MYC。结果,肿瘤抑制性的miR-15和let-7家族的转录水平增加,它们分别靶向并降低了关键的促生存基因BCL-2和BCL-XL的表达。HDAC抑制后BCL-2和BCL-XL的下调也需要MYC。阻断BCL-2和BCL-XL的3'-非翻译区中miR-15和let-7家族的结合位点可防止HDAC抑制诱导的细胞凋亡。这些结果为HDAC抑制诱导乳腺癌和肺癌细胞死亡的分子基础提供了重要见解,并揭示了在HDAC抑制作用下被激活的MYC调节的miRNA的肿瘤抑制作用。